COQ10 AND GPI 1485 IN SUBJECTS WITH EARLY UNTREATED PARKINSON'S

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Parkinson's disease (PD) is one of the most common adult-onset neurodegenerative disorders, affecting approximately 1 million people in North America. PD can cause problems with tremors, movement, balance, and thinking that progress over time. This is a pilot study of 2 agents that may slow the progression of Parkinson's Disease (PD): CoEnzyme Q10 and GPI 1485. CoEnzyme Q10 (CoQ) is an antioxidant that may slow damage to cells important in Parkinson's disease. GPI 1485 (GPI) is a substance that may cause nerve growth in the brain. This study will occur at 42 sites and will enroll 195 subjects with early, untreated PD, ages 30 or older. Subjects will be randomly assined to CoQ, GPI, or placebo. Randomly means by chance, like flipping a coin. Placebo means an inactive substance that looks like CoQ or GPI, but is not expected to have any effect on PD. Subjects will be monitored for 12 months, and their disease progression will be tracked. During this time, subjects will complete a screening visit and 6 monitoring visits. The main outcome to be examined is the change in a rating scale known as the Unified Parkinson Disease Rating Scale (UPDRS).